Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z-Drugs: A Target Trial Emulation.
文献摘要
Background Lemborexant and suvorexant are widely used dual orexin receptor antagonists (DORAs) for the pharmacological treatment of insomnia. Although they are generally considered safer than benzodiazepine receptor agonists (Z-drugs) regarding adverse events including hip fractures, evidence from direct comparisons remains limited. This study aimed to examine whether lemborexant and suvorexant are associated with a lower risk of hip fracture than Z-drugs in older individuals. Methods We conducted a cohort study using databases from Tochigi Prefecture, Japan. We included individuals aged ≥ 65 years who newly initiated either lemborexant or Z-drugs (lemborexant analysis cohort) or either suvorexant or Z-drugs (suvorexant analysis cohort). The primary outcome was hospitalization for hip fracture within 1 year of cohort entry. Per-protocol effects of continuous treatment with the assigned drugs were estimated. Baseline confounding was adjusted using inverse probability of treatment weighting based on propensity scores. Censoring due to discontinuation of the assigned drug or switching to the comparator drug was adjusted for using inverse probability of censoring weights. Adjusted cumulative incidence and hazard ratios (HRs) were estimated using the Kaplan-Meier methods and Cox regression, respectively. Results The lemborexant analysis cohort included 22,655 individuals (6879 and 15,776 in the lemborexant and Z-drug groups, respectively). After adjustment, lemborexant use was associated with a significantly lower hip fracture incidence (HR, 0.31, 95% confidence interval [CI], 0.16-0.59, p Conclusion DORAs, particularly lemborexant, may be safer alternatives to Z-drugs with respect to hip fracture risk.